financetom
Business
financetom
/
Business
/
Why Is AeroVironment Stock Tanking Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is AeroVironment Stock Tanking Wednesday?
Mar 11, 2026 3:53 AM

AeroVironment Inc. ( AVAV ) shares tumbled more than 9% in Wednesday’s premarket trading after the defense technology company reported quarterly earnings and revenue that missed Wall Street expectations and lowered its fiscal 2026 profit outlook.

Earnings, Revenue Fall Short of Estimates

AeroVironment ( AVAV ) reported third-quarter fiscal 2026 earnings of 64 cents per share, missing the consensus estimate of 69 cents per share.

Quarterly revenue totaled $408.05 million, also below the Street estimate of $475.63 million, representing a 14.21% shortfall.

Despite the miss, revenue for the third quarter of fiscal 2026 rose 143% year over year, driven by higher product sales and increased service revenue.

Fiscal 2026 Guidance Reduced

The company also lowered its fiscal 2026 adjusted earnings outlook, projecting earnings of $2.75 to $3.10 per share. The new forecast is below both its prior guidance of $3.40 to $3.55 per share and the analyst estimate of $3.31 per share.

CEO Points to Strong Demand

“While our third quarter results were impacted by revenue timing and adjustments in our Space business, demand for our unique solutions remains robust,” said Wahid Nawabi, AeroVironment ( AVAV ) chairman, president and CEO.

“Strong order flow and growth in funded backlog during the quarter are setting the stage for record fourth quarter revenue and a solid start to fiscal year 2027,” Nawabi commented on Tuesday.

As of January 31, 2026, AeroVironment ( AVAV ) reported a funded backlog of $1.1 billion, up from $726.6 million as of April 30, 2025, reflecting rising demand for the company’s defense and aerospace technologies.

Impairment Charges

The company recorded a $151.3 million goodwill impairment in the third quarter of fiscal 2026 after receiving a January 2026 stop-work order related to its Other Transaction Agreement to deliver BADGER phased array antenna systems for the Space Force’s Satellite Communication Augmentation Resource (SCAR) program.

Management determined the order was a triggering event, indicating that the carrying value of the Space reporting unit exceeded its fair value.

Following the order, the company revised its long-term cash flow projections for the Space unit to reflect lower expected revenue tied to the paused program.

The updated outlook also factors in higher anticipated research and development spending and capital investments required to commercialize the product.

Technical Analysis

The stock is currently trading 18.6% below its 20-day simple moving average (SMA) and 31.7% below its 100-day SMA, demonstrating significant weakness.

Shares have increased 78.69% over the past 12 months and are currently positioned closer to their 52-week lows than highs.

The RSI is at 40.00, which is considered neutral territory. Meanwhile, MACD is at -15.6354, below its signal line at -14.2451, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $202.50

Key Support: $196.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $352.78. Recent analyst moves include:

Canaccord Genuity: Buy (Lowers Target to $330.00) (March 4)

RBC Capital: Outperform (Lowers Target to $325.00) (March 3)

Baird: Outperform (Lowers Target to $260.00) (March 3)

Benzinga Edge Scorecard

Below is the Benzinga Edge scorecard for AeroVironment ( AVAV ), highlighting its strengths and weaknesses compared to the broader market:

Momentum: Bullish (Score: 86.09) — Stock is outperforming the broader market.

The Verdict: AeroVironment’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum (86.09) confirms the strong trend, the extremely low Value score warns that the stock is priced for perfection—investors should ride the trend but use tight stop-losses.

Top ETF Exposure

SPDR S&P Aerospace & Defense ETF : 4.49% Weight

ARK Autonomous Technology & Robotics ETF ( ARKQ ) : 3.99% Weight

ARK Space & Defense Innovation ETF ( ARKX ) : 6.80% Weight

AVAV Price Action: AeroVironment ( AVAV ) shares were down 9.30% at $200.97 during premarket trading on Wednesday, according to Benzinga Pro data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- Pfizer ( PFE ) on Tuesday reported positive results from a trial evaluating Braftovi in combination with cetuximab and Folfiri in patients with previously untreated metastatic colorectal cancer. The regimen showed a statistically significant and clinically meaningful improvement in progression-free survival, a key secondary endpoint, Pfizer ( PFE ) said. Overall survival, a...
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Mar 11, 2026
08:13 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that the Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. The ongoing pivotal Phase 3 study is being conducted...
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data. The company said the board, which neets quarterly in accordance...
Sherritt International to Pause Moa Mining Operations in Cuba Due to Fuel Constraints
Sherritt International to Pause Moa Mining Operations in Cuba Due to Fuel Constraints
Mar 11, 2026
08:11 AM EST, 02/17/2026 (MT Newswires) -- Sherritt International ( SHERF ) said Tuesday that it has reduced operations at its Moa joint venture in Cuba due to fuel supply constraints affecting the country. The company said it expects to pause mining operations and place the processing plant on standby within the next week during which time, planned maintenance activities...
Copyright 2023-2026 - www.financetom.com All Rights Reserved